Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF)
(“Satellos” or the “Company”), a public biotech
company developing new small molecule therapeutic approaches to
improve the treatment of muscle diseases and disorders, announced
today the appointment of Stephanie Brown to its Board of Directors.
Ms. Brown brings over 30 years of biopharma industry experience,
having held numerous executive roles contributing to groundbreaking
achievements in product commercialization and organizational
transformation.
“Stephanie is a recognized leader in the biopharma space and has
led multiple successful product launches for biologics and small
molecules, particularly within the rare diseases sector,” said
Frank Gleeson, Co-founder and CEO of Satellos Bioscience. “Her
exceptional experience in building and scaling biopharma companies,
particularly in rare and specialty disease markets, aligns well
with Satellos’ mission to innovate for patients with serious muscle
diseases. Her expertise will be invaluable as we advance
transformative treatments and position the Company for future
growth.”
Over her career, Ms. Brown’s contributions have spanned business
development, portfolio planning, and corporate optimization with
revenues reaching billions. Ms. Brown has held senior leadership
roles, including President, North America for Santhera
Pharmaceuticals, where she oversaw operations and strategic
objectives, and Head of Rare Diseases at Ipsen Biopharmaceuticals,
where she directed the commercialization strategy for in-line and
launch brands. She has also been a vital member of executive teams
at top global firms, including Merck, Genentech, Biogen, Takeda
Pharmaceuticals, and Novartis, where she managed high-value product
portfolios and led launches for multiple specialty and rare disease
treatments, including the successful launch of Aimovig, a
breakthrough migraine prevention therapy.
Currently, Stephanie serves on the Board of Directors for
Resilia, Inc. She has previously held board positions with ObsEva
and the Biotechnology Innovation Organization (BIO), among others,
contributing her expertise to the advancement of biotech
innovations and patient-centered solutions.
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company dedicated
to developing life-improving medicines to treat degenerative muscle
diseases. Satellos has invented SAT-3247 as a first-of-its-kind,
orally administered small molecule drug designed to restore
skeletal muscle regeneration initially in Duchenne muscular
dystrophy (DMD). Satellos has generated a significant body of
preclinical evidence in DMD to support that correcting muscle stem
cell polarity with SAT-3247 has the potential to restore skeletal
muscle regeneration to repair and strengthen muscle that has been
damaged. The Company’s lead drug candidate SAT-3247 is currently in
clinical development as a potential disease-modifying treatment
DMD. Additionally, Satellos is leveraging its breakthrough research
in muscle stem cell polarity and proprietary discovery platform
MyoReGenX™, to identify degenerative muscle diseases where deficits
in muscle regeneration occur that are amenable to therapeutic
intervention for future clinical development. For more information,
visit www.satellos.com.
Notice on Forward-Looking Statements
This press release includes forward-looking information or
forward-looking statements within the meaning of applicable
securities laws regarding Satellos and its business, which may
include, but are not limited to, statements regarding the potential
of our approach in other degenerative muscle diseases or in muscle
injury or trauma; the general benefits of modulating stem cell
polarity by administering small molecule drugs; its/their
prospective impact on Duchenne patients, patients with other
degenerative muscle disease or muscle injury or trauma, and on
muscle regeneration generally; the utility of regenerating muscle
by modulating polarity; adoption of Satellos’ approach by the
medical community; and Satellos’ technologies and drug development
plans. All statements that are, or information which is, not
historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, occurrences or developments, are
“forward-looking information or statements.” Often but not always,
forward-looking information or statements can be identified by the
use of words such as “shall”, “intends”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”,
“prospective” , “assert” or any variations (including negative or
plural variations) of such words and phrases, or state that certain
actions, events or results “may”, “might”, “can”, “could”, “would”
or “will” be taken, occur, lead to, result in, or, be achieved.
Such statements are based on the current expectations and views of
future events of the management of the Company. They are based on
assumptions and subject to risks and uncertainties. Although
management believes that the assumptions underlying these
statements are reasonable, they may prove to be incorrect. The
forward-looking events and circumstances discussed in this release,
may not occur and could differ materially as a result of known and
unknown risk factors and uncertainties affecting the Company,
including, without limitation, risks relating to the pharmaceutical
and bioscience industry (including the risks associated with
preclinical and clinical trials and regulatory approvals), and the
research and development of therapeutics, the results of
preclinical and clinical trials, general market conditions and
equity markets, economic factors and management’s ability to manage
and to operate the business of the Company generally, including
inflation and the costs of operating a biopharma business, and
those risks listed in the “Risk Factors” section of Satellos’
Annual Information Form dated March 26, 2024 (which is located on
Satellos’ profile at www.sedarplus.ca). Although Satellos has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward- looking statement can be guaranteed.
Except as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Satellos does not undertake any obligation to publicly update or
revise any forward-looking statement, whether resulting from new
information, future events, or otherwise
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241114757987/en/
Investors: Liz Williams, CFO, ir@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com,
+1.858.344.8091
Satellos Bioscience (TSX:MSCL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Satellos Bioscience (TSX:MSCL)
Historical Stock Chart
From Dec 2023 to Dec 2024